”Oncosil is a commercial stage DRUG developer...” ”Safety profile of the DRUG is outstanding....”
Yes indeed, BP are experts in the field all right..... The only experts in the field, the ones with opinions that really count now are the doctors treating this cancer. OSL has unfortunately demonstrated its messaging around its trial data isn’t credible, and Bell Potter IMO are Oncosil’s underwriting mouthpiece who cut & paste and parrot the same faulty messages. Helpfully Dr Paul Ross (London) the Panco trial lead researcher has his contact details on the poster so I might consider emailing him to see if he’s willing to share his opinion on a few things such as the naive meta-analysis comparison ((the other poster) and whether he agrees with the company claims about Panco results.
OSL Price at posting:
13.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)